Loading institutional data...
Loading institutional data...
Held by 388 of 2,417 reporting institutions (98th percentile) — extremely crowded.
Data as of Q3 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading analysis...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading insider activity...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Ranked against 23 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-09-30.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | $1.15T | 56.1× | — | 17.6× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 1,730 |
| JNJ | $652.5B | 24.6× | 20.7× | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | 0.9× | 1,839 |
| ABBV | $505.4B | 121.2× | 35.8× | 8.3× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 3.9× | 1,635 |
| MRK | $347.7B | 19.4× | — | 5.3× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 1,469 |
| ABT | $177.6B | 27.6× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 0.5× | 1,081 |
| PFE | $167.9B | 21.6× | — | 2.7× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 1,034 |
| VRTX | $134.3B | 34.6× | 29.5× | 11.2× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | -1.2× | 568 |
| BMY | $123.7B | 17.5× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 904 |
| REGN | $83.7B | 19.6× | 20.0× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | -0.3× | 408 |
| TEVA | $46.6B | 33.0× | 17.4× | 2.7× | 4.3% | 51.8% | 8.2% | 17.8% | 14.5% | -0.7× | 7 |
| ONC | $42.5B | — | 66.1× | 8.0× | 40.2% | 87.5% | 5.4% | 6.6% | 5.4% | -6.1× | 61 |
| ZTS | $32.1B | 12.9× | 10.2× | 3.4× | 2.3% | 71.8% | 28.2% | 78.3% | 21.5% | 1.7× | 388 |
| ALNY | $31.1B | 99.7× | 52.9× | 8.4× | 65.2% | 81.8% | 8.4% | 39.8% | 39.8% | -3.0× | 163 |
| RPRX | $28.9B | 36.4× | 23.8× | 12.1× | 5.1% | — | 32.4% | 7.9% | 4.1% | 5.3× | 161 |
| UTHR | $25.2B | 21.1× | 14.9× | 7.9× | 10.6% | 87.9% | 41.9% | 18.8% | 18.8% | -1.0× | 202 |
| INSM | $21.2B | — | — | 34.9× | 66.7% | 79.7% | -211% | -173% | -99.8% | — | 154 |
| ELAN | $11.3B | — | — | 2.4× | 6.2% | 55.0% | -4.9% | -3.5% | -2.2% | — | 122 |
| BMRN | $10.8B | 31.1× | 20.7× | 3.4× | 12.9% | 77.7% | 10.8% | 5.7% | 5.2% | -1.5× | 119 |
| CORT | $9.3B | 105.2× | — | 12.3× | 12.8% | 98.3% | 13.1% | 15.4% | 15.4% | -2.6× | 107 |
| TGTX | $8.8B | 20.7× | 72.6× | 14.3× | 87.3% | 83.7% | 72.6% | 69.0% | 50.0% | 1.4× | 99 |
| ALKS | $7.6B | 31.6× | 25.6× | 5.1× | -5.2% | 86.7% | 16.4% | 13.3% | 13.3% | -1.4× | 74 |
| IONS | $7.5B | — | — | 7.9× | 33.8% | 98.3% | -40.4% | -78.0% | -17.0% | — | 81 |
| KNSA | $7.4B | 126.9× | 93.8× | 11.0× | 60.1% | 88.5% | 8.7% | 10.4% | 10.4% | -2.1× | 1 |
| AMRX | $7.4B | 96.1× | 21.4× | 2.4× | 8.0% | 36.9% | 2.4% | -102% | 2.9% | 5.1× | 73 |
Peers = companies sharing ZTS's sector (Pharmaceutical Preparations) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Solve the discounted cash flow backwards, then stress-test the assumptions.
Average free cash flow across the last 3 positive fiscal years (FY2023, FY2024, FY2025). Smooths the cycle. Stock compensation is NOT charged — it is added back inside operating cash flow.
To be worth $78.80 today, the market must believe free cash flow compounds 0.3%/yr for a decade (off $2.07B on the 3-yr avg basis).
On the basis ($2.00B) the requirement is 0.8%/yr. Shares issued to employees are added back in operating cash flow, so this basis treats them as free.
The market's 0.3% is more conservative than its 9-yr track record.
Default is 7.0% — this company's computed cost of capital (computed WACC), the same rate the Analysis tab discounts at.
2-stage DCF · 0.41B shares (market data) · net debt $6.59B
mean 24.0% · volatility σ 43% · implied rate exceeded in 6/9 yrs
Central path = implied 0.3%/yr growth; shaded band = ±1σ (43%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $3.23B buybacks = $3.23B returned on $2.28B FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 21%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
EOD close · as of 2026-10-29
How a revenue dollar becomes profit — FY2025
Dividends and buybacks are cash paid out, shown here against the same year's profit for scale — not funded from it. This year they exceeded net income, so the ribbons are capped at earnings and understate what was actually returned.
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.47B 100.0% | $9.26B 100.0% | $8.54B 100.0% | $8.08B 100.0% | $7.78B 100.0% | $6.67B 100.0% | $6.26B 100.0% | $5.83B 100.0% | $5.31B 100.0% | $4.89B 100.0% |
| Cost of Revenue | $2.67B 28.2% | $2.72B 29.4% | $2.56B 30.0% | $2.45B 30.4% | $2.30B 29.6% | $2.06B 30.8% | $1.99B 31.8% | $1.91B 32.8% | $1.77B 33.4% | $1.67B 34.1% |
| Selling, General & Admin | $2.38B 25.1% | $2.32B 25.0% | $2.15B 25.2% | $2.01B 24.9% | $2.00B 25.7% | $1.73B 25.9% | $1.64B 26.2% | $1.48B 25.5% | $1.33B 25.1% | $1.36B 27.9% |
| Interest Expense | $222.0M 2.3% | $225.0M 2.4% | $239.0M 2.8% | $221.0M 2.7% | $224.0M 2.9% | $231.0M 3.5% | $223.0M 3.6% | $206.0M 3.5% | $175.0M 3.3% | $166.0M 3.4% |
| Other Income (Expense), net | $36.0M 0.4% | $19.0M 0.2% | $159.0M 1.9% | -$40.0M -0.5% | -$48.0M -0.6% | -$17.0M -0.3% | $57.0M 0.9% | $83.0M 1.4% | -$6.0M -0.1% | $2.0M 0.0% |
| Pretax Income | $3.36B 35.5% | $3.13B 33.8% | $2.94B 34.4% | $2.66B 32.9% | $2.49B 32.0% | $2.00B 29.9% | $1.80B 28.8% | $1.69B 29.0% | $1.52B 28.7% | $1.23B 25.1% |
| Income Tax Expense | $687.0M 7.3% | $637.0M 6.9% | $596.0M 7.0% | $545.0M 6.7% | $454.0M 5.8% | $360.0M 5.4% | $301.0M 4.8% | $266.0M 4.6% | $663.0M 12.5% | $409.0M 8.4% |
| Net Income | $2.67B 28.2% | $2.49B 26.9% | $2.34B 27.4% | $2.11B 26.2% | $2.04B 26.2% | $1.64B 24.5% | $1.50B 24.0% | $1.43B 24.5% | $864.0M 16.3% | $821.0M 16.8% |
| Per Share | ||||||||||
| EPS (Basic) | $6.03 | $5.47 | $5.08 | $4.51 | $4.29 | $3.44 | $3.14 | $2.96 | $1.76 | $1.66 |
| EPS (Diluted) | $6.02 | $5.47 | $5.07 | $4.49 | $4.27 | $3.42 | $3.11 | $2.93 | $1.75 | $1.65 |
| Weighted Avg Shares (Basic) | 443.4M | 454.2M | 461.2M | 468.9M | 474.3M | 475.5M | 478.1M | 483.1M | 489.9M | 495.7M |
| Weighted Avg Shares (Diluted) | 443.8M | 454.8M | 462.3M | 470.4M | 476.7M | 478.6M | 481.8M | 486.9M | 493.2M | 498.2M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $2.45B (at 2025-12-31) covers the $750.0M due within a year 3.3× over. Scheduled principal only (excludes interest & revolver draws). As of 2026-06-30 (10-Q). The cash figure is from 2025-12-31, so the two are not the same balance-sheet date — the schedule has not been refiled since.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit. Effective rate ~2.5% on $9.04B of debt.
Cash of $2.45B fully covers short-term debt of $0.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-10-29
Where each multiple sits in its own 13-yr range · 2th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 13-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
ROE 78% against ROIC 21% — 57% of the return on equity comes from leverage and buybacks rather than from the operating business.
Equity is the year-end figure. On average equity over the two year-ends, ROE is 65.3% — the two diverge when buybacks or issuance move equity during the year.
What the company owes vs. what it holds
This shows debt/cash structure and net leverage. The year-by-year maturity schedule is on the Debt & Leverage tab.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 3.0× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 32.8 | 31.8 | 30.8 | 29.6 | 30.4 | 30.0 | 29.4 | 28.2 |
| SG&A | 25.5 | 26.2 | 25.9 | 25.7 | 24.9 | 25.2 | 25.0 | 25.1 |
| Income Tax | 4.6 | 4.8 | 5.4 | 5.8 | 6.7 | 7.0 | 6.9 | 7.3 |
| Net Income | 24.5 | 24.0 | 24.5 | 26.2 | 26.2 | 27.4 | 26.9 | 28.2 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on ZTS: price, valuation and headline fundamentals from SEC filings. The four questions at the top of the page are where the judgements live.
Earns 17.67pts above its cost of capital, positive in 5 of the last 5 years.
| Period | ROIC | Cost of capital | Spread |
|---|---|---|---|
| FY2019 | 18.4% | 7.0% (today's — no rate published for this year) | 11.4pts |
| FY2020 | 20.8% | 7.0% (today's — no rate published for this year) | 13.8pts |
| FY2021 | 25.3% | 5.4% | 19.8pts |
| FY2022 | 23.6% | 7.8% | 15.8pts |
| FY2023 | 22.3% | 8.0% | 14.2pts |
| FY2024 | 25.4% | 8.1% | 17.3pts |
| FY2025 | 25.3% | 6.8% | 18.5pts |
| Now | 21.5% | 7.0% | 14.4pts |
| Fiscal year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY2016 | 65.9% | 25.1% | 16.8% |
| FY2017 | 66.6% | 28.8% | 16.3% |
| FY2018 | 67.2% | 27.6% | 24.5% |
| FY2019 | 68.2% | 27.9% | 24.0% |
| FY2020 | 69.2% | 30.2% | 24.5% |
| FY2021 | 70.4% | 32.6% | 26.2% |
| FY2022 | 69.6% | 33.4% | 26.2% |
| FY2023 | 70.0% | 32.5% | 27.4% |
| FY2024 | 70.6% | 33.6% | 26.9% |
| FY2025 | 71.8% | 35.1% | 28.2% |
ROIC ex-goodwill is 33.33% against 24.71% reported — the return is earned on a capital base inflated by what was paid for acquisitions, not by the operating business alone.
Converts 0.79x of reported profit into cash — adequate, without much margin.
No material counter-signal in the checked set: FCF / net income over 3 and 5 years, Sloan accruals, SBC as a share of revenue, SBC as a share of operating cash flow, SBC-adjusted free cash flow, free cash flow per diluted share, buybacks against SBC issued, capex vs depreciation, free cash flow against revenue, share count since the first year on file, cash conversion cycle (DSO, DIO, DPO), receivables growth against revenue growth.
Covers interest 10.5x even after a 30% EBITDA decline.
| EBITDA decline | Interest coverage |
|---|---|
| 0% | 14.97x |
| 5% | 14.22x |
| 10% | 13.48x |
| 15% | 12.73x |
| 20% | 11.98x |
| 25% | 11.23x |
| 30% | 10.48x |
| 35% | 9.73x |
| 40% | 8.98x |
| 45% | 8.24x |
| 50% | 7.49x |
| 55% | 6.74x |
| 60% | 5.99x |
Ladder as of 2026-06-30 (10-Q); cash from the 2025-12-31 balance sheet; FCF from FY2025.
Balance sheet at 2025-12-31. Undrawn revolving credit is not shown: the tag is collected but not yet mapped through to the API.
The maturity schedule is not part of this verdict — its filing anchor is often older than the balance sheet it sits beside, so a wall inside 24 months may not be visible here.
At $77.80, free cash flow must compound 0.28%/yr for 10 years. It has done 9.35%/yr over 6 years.
| Fiscal year | FCF growth | Price requires |
|---|---|---|
| FY2020 | 25.3% | 0.3% |
| FY2021 | 3.8% | 0.3% |
| FY2022 | −23.6% | 0.3% |
| FY2023 | 22.2% | 0.3% |
| FY2024 | 41.8% | 0.3% |
| FY2025 | −0.7% | 0.3% |
The percentile ranks the FISCAL-YEAR point, because the distribution behind each strip is built from fiscal-year closes — ranking a TTM figure inside it would compare two different bases. TTM basis: TTM.
The implied rate has been matched or beaten in 4 of the last 6 years.
Leverage and buybacks account for 57 points of the 78% return on equity in FY2025. The business earns 21% on the capital it employs; the rest is balance sheet.
ROE is on average equity; ROIC is NOPAT over average invested capital (debt plus equity less excess cash). The gap is not a single adjustment.
$2.8B of goodwill — 26% of invested capital. The gap is what was paid above the fair value of what was bought; it is real capital shareholders provided, so neither bar is the whole answer.
| Step | Amount | Running total |
|---|---|---|
| Net income | $2.67B | $2.67B |
| Share-based comp | $83M | $2.76B |
| Other non-cash & working capital | $148M | $2.90B |
| Operating cash flow | $2.90B | $2.90B |
| Capex | −$621M | $2.28B |
| Free cash flow | $2.28B | $2.28B |
| FCF after SBC | $2.20B | $2.20B |
| Fiscal year | Revenue growth | Receivables growth | Gap |
|---|---|---|---|
| FY2020 | 6.6% | -6.7% | -13.3 points |
| FY2021 | 16.5% | 11.8% | -4.6 points |
| FY2022 | 3.9% | 7.2% | 3.3 points |
| FY2023 | 5.7% | 7.3% | 1.6 points |
| FY2024 | 8.3% | 0.9% | -7.4 points |
| FY2025 | 2.3% | 7.1% | 4.8 points |
| Fiscal year | DSO | DIO | DPO | Cash conversion cycle |
|---|---|---|---|---|
| FY2019 | 63.3 days | 258.4 days | 55.2 days | 266.5 days |
| FY2020 | 55.4 days | 288.9 days | 81.1 days | 263.2 days |
| FY2021 | 53.2 days | 304.8 days | 69.1 days | 288.9 days |
| FY2022 | 54.9 days | 348.8 days | 60.2 days | 343.4 days |
| FY2023 | 55.7 days | 365.4 days | 58.6 days | 362.6 days |
| FY2024 | 51.9 days | 309.6 days | 58.1 days | 303.3 days |
| FY2025 | 54.3 days | 337.3 days | 60.9 days | 330.7 days |
| Fiscal year | Accruals / assets |
|---|---|
| FY2019 | -2.6 percent |
| FY2020 | -3.6 percent |
| FY2021 | -1.3 percent |
| FY2022 | 1.4 percent |
| FY2023 | -0.1 percent |
| FY2024 | -3.3 percent |
| FY2025 | -1.5 percent |
Below the line, the asset base is being consumed faster than it is replaced.
Depreciation here includes amortisation of acquired intangibles — goodwill written down over time, customer lists, acquired technology. Capex does not replace those and is not meant to, so an acquisitive or asset-light company sits below 1.0 permanently and correctly. The signal is cleanest for capital-intensive businesses, where the two measure the same physical base. For that reason this informs the earnings-quality verdict but never caps it.
SBC is added back inside operating cash flow, so reported free cash flow treats shares issued to employees as free. Percent of revenue says how expensive the payroll is; percent of operating cash flow says how much of the cash exists only because the charge was added back. The buyback offset is buybacks over SBC — below 1.0 the repurchase does not cover the shares issued.
Figures are the latest fiscal year (FY2025) from the company's own filings, not a trailing-twelve-month window — Q2 reads fiscal years throughout so the cash-conversion ratios and these share one basis. A blank is a line the filer did not report; it is never read as zero.
Last reported position per insider, carried forward. Steps can be a holding disclosed for the first time rather than a trade.
| Date | Insider | What it was | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-10-09 | Peck Kristin C Chief Executive Officer | Grant | 720 | $26.17 | — |
| 2026-10-09 | Lagano Roxanne Executive Vice President | Grant | 368 | $26.17 | — |
| 2026-10-09 | Esch Kevin Executive Vice President | Grant | 360 | $26.17 | — |
| 2026-10-09 | Nayak Abhay U Executive Vice President | Grant | 321 | $26.17 | — |
| 2026-10-09 | Driscoll Rimma |
Every row is classified by what it MEANT, not by its SEC code. A code is not a meaning: code P (“purchase”) also covers dividend reinvestment and employee stock purchase plans, and code S (“sale”) also covers 10b5-1 plan sales scheduled months earlier and option exercises sold the same day.
Across 30 days of all filings, $5.08bn of insider selling contained $3.50bn of plan sales and $0.46bn of exercise-and-sell. Only 29% was discretionary. Reading an unclassified feed badly overstates how much insiders decided.
Buys and sales are counted separately and never netted. They are different decisions by different people; a company where one officer bought while another sold is not “neutral”.
The holding line carries each insider's last reported position forward, so it shows the total held rather than a sawtooth of whoever traded that day. It covers only insiders who filed in the window.
“Filed late” counts calendar days past the two-business-day deadline with five days' grace, so a Thursday or Friday trade crossing a weekend is never flagged. It describes the company's filing discipline, not the trade.
Insider activity is descriptive. Nothing here is investment advice.
| Grant |
| 278 |
| $26.17 |
| — |
| 2026-10-09 | Ferran Astorga Jeannette Executive Vice President | Grant | 53 | $26.17 | — |
| 2026-10-09 | Fuller Julie Executive Vice President | Grant | 368 | $26.17 | — |
| 2026-10-09 | Sarbaugh Keith Executive Vice President | Grant | 303 | $26.17 | — |
| 2026-09-30 | 3 co-filers Executive Vice President | Option exercise | 799 | — | — |
| 2026-09-30 | 3 co-filers Executive Vice President | Tax withholding | 274 | $69.83 | $19k |
| 2026-09-30 | 3 co-filers Executive Vice President | Option exercise | 799 | — | — |
| 2026-09-17 | Stetter Mark Director | Grant | 342 | $73.02 | — |
| 2026-08-31 | Saccaro James EVP, CFO & COO | Grant | 81,063 | $0.00 | — |
| 2026-08-07 | Damelio Frank A Director | Gift | 6,650 | $0.00 | $0 |
| 2026-07-10 | Sarbaugh Keith Executive Vice President | Grant | 260 | $26.22 | — |
| 2026-07-10 | Peck Kristin C Chief Executive Officer | Grant | 616 | $26.22 | — |
| 2026-07-10 | Nayak Abhay U Executive Vice President | Grant | 215 | $26.22 | — |
| 2026-07-10 | Esch Kevin Executive Vice President | Grant | 308 | $26.22 | — |
| 2026-07-10 | Driscoll Rimma Executive Vice President | Grant | 238 | $26.22 | — |
| 2026-07-10 | Fuller Julie Executive Vice President | Grant | 315 | $26.22 | — |
| 2026-07-10 | Lagano Roxanne Executive Vice President | Grant | 315 | $26.22 | — |
| 2026-07-10 | Ferran Astorga Jeannette Executive Vice President | Grant | 45 | $26.22 | — |
| 2026-07-10 | Joseph Wetteny Chief Financial Officer | Grant | 363 | $26.22 | — |
| 2026-06-18 | Stetter Mark Director | Grant | 318 | $78.71 | — |
| 2026-06-10 | Mccallister Michael B Director | Gift | 1,209 | $0.00 | $0 |
| 2026-05-21 | 2 co-filers Group filing | Option exercise | 1,572 | — | — |
| 2026-05-21 | 2 co-filers Group filing | Option exercise | 1,572 | — | — |
| 2026-05-20 | 4 co-filers Group filing | Option exercise | 1,944 | — | — |
| 2026-05-20 | 4 co-filers Group filing | Option exercise | 10,186 | — | — |
| 2026-05-20 | 4 co-filers Group filing | Option exercise | 1,944 | $0.00 | — |
| 2026-05-20 | 4 co-filers Group filing | Option exercise | 10,187 | $0.00 | — |
| 2026-05-13 | Damelio Frank A Director | Open-market buy | 6,650 | $75.39 | $501k |
| 2026-05-13 | Bisaro Paul Director | Open-market buy | 2,000 | $75.88 | $152k |
| 2026-05-11 | Mccallister Michael B Director | Open-market buyindirect | 3,000 | $77.76 | $233k |
| 2026-04-30 | 3 co-filers Executive Vice President | Option exercise | 259 | — | — |
| 2026-04-30 | 3 co-filers Executive Vice President | Tax withholding | 75 | $114.97 | $9k |
| 2026-04-30 | 3 co-filers Executive Vice President | Option exercise | 260 | — | — |
| 2026-04-10 | Fuller Julie Executive Vice President | Grant | 551 | $39.64 | — |
| 2026-04-10 | Lagano Roxanne Executive Vice President | Grant | 551 | $39.64 | — |
| 2026-04-10 | Ferran Astorga Jeannette Executive Vice President | Grant | 5 | $39.64 | — |